

Selective Monocationic Inhibitors of Neuronal Nitric Oxide Synthase. Binding Mode Insights from Molecular Dynamics Simulations

He Huang,[†] Haitao Ji,^{†,‡} Huiying Li,[§] Qing Jing,[†] Kristin Jansen Labby,[†] Pavel Martásek,^{||,⊥} Linda J. Roman,^{||} Thomas L. Poulos,^{*,§} and Richard B. Silverman^{*,†}

[†]Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, and Center for Molecular Innovation and Drug Discovery, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208-3113, United States


[§]Departments of Molecular Biology and Biochemistry, Pharmaceutical Sciences, and Chemistry, University of California, Irvine, California 92697-3900, United States

^{||}Department of Biochemistry, University of Texas Health Science Center, San Antonio, Texas 78384-7760, United States

[⊥]Department of Pediatrics, First School of Medicine, Charles University, Prague, Czech Republic

Supporting Information

ABSTRACT: The reduction of pathophysiologic levels of nitric oxide through inhibition of neuronal nitric oxide synthase (nNOS) has the potential to be therapeutically beneficial in various neurodegenerative diseases. We have developed a series of pyrrolidine-based nNOS inhibitors that exhibit excellent potencies and isoform selectivities (*J. Am. Chem. Soc.* **2010**, *132*, 5437). However, there are still important challenges, such as how to decrease the multiple positive charges derived from basic amino groups, which contribute to poor bioavailability, without losing potency and/or selectivity. Here we present an interdisciplinary study combining molecular docking, crystallography, molecular dynamics simulations, synthesis, and enzymology to explore potential pharmacophoric features of nNOS inhibitors and to design potent and selective monocationic nNOS inhibitors. The simulation results indicate that different hydrogen bond patterns, electrostatic interactions, hydrophobic interactions, and a water molecule bridge are key factors for stabilizing ligands and controlling ligand orientation. We find that a heteroatom in the aromatic head or linker chain of the ligand provides additional stability and blocks the substrate binding pocket. Finally, the computational insights are experimentally validated with double-headed pyridine analogues. The compounds reported here are among the most potent and selective monocationic pyrrolidine-based nNOS inhibitors reported to date, and **10** shows improved membrane permeability.



INTRODUCTION

The key physiologic mediator, nitric oxide (NO), which plays an important role in the regulation of various biological processes, is produced in mammalian cells by three distinct nitric oxide synthases (NOs): neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS).^{1,2} The three isoforms share significant sequence homology (~50%) and catalyze the oxidation of L-arginine to NO and citrulline with NADPH and O₂ as co-substrates.^{3,4} Each isoform consists of an N-terminal oxygenase domain that binds heme, substrate, and tetrahydrobiopterin (H₄B); a central linker region that binds calmodulin; and a C-terminal reductase domain with binding sites for FAD, FMN, and NADPH.^{5,6}

NO overproduction by nNOS has been associated with chronic neurodegenerative pathologies including Alzheimer's, Parkinson's, and Huntington's diseases as well as neuronal damage resulting from stroke, cerebral palsy, and migraine headaches.^{1,7-10} The reduction in pathophysiologic levels of NO through inhibition of nNOS has the potential to be beneficial as an approach to develop new therapeutics for these diseases.^{11,12} However, the therapeutic control of NO synthesis

is difficult because of the challenge to achieve highly selective inhibition of the specific isoforms.¹³ Each one of the three isozymes is associated with different functions: nNOS is devoted to neuronal signaling, iNOS to the immune response, and eNOS to smooth muscle relaxation and blood pressure regulation.¹⁴ Therefore, selective inhibition of nNOS over the other isozymes is highly desirable for the treatment of neurodegenerative diseases to avoid undesirable effects related to iNOS and eNOS inhibition.¹⁵⁻¹⁹

In our continuous efforts to develop nNOS-selective inhibitors, we established a new approach for fragment-based *de novo* design and discovered a series of highly potent and nNOS-selective small-molecule inhibitors with a 2-aminopyridinomethyl pyrrolidine scaffold, including **1a**, **1b**, **2a**, and **2b** (Figure 1).²⁰⁻²⁴ There are two chiral centers (the 3' and 4' carbons) in each structure. *In vitro* enzyme assays of the enantiopure compounds indicate that (3'R,4'R)-enantiomers **1b** and **2b** are much more potent and selective for nNOS than

Received: March 7, 2012

Published: June 25, 2012




Figure 1. Chemical structures of 1–3.




Figure 2. Crystallographic binding conformation of 2a (A, PDB ID 3NLK) and 2b (B, PDB ID 3NLM) in rat nNOS.

(3'S,4'S)-analogues **1a** and **2a**.^{20,21} These pyrrolidine-based inhibitors were designed from structure–activity studies based on a series of dipeptide inhibitors.²⁵ The 2-aminopyridine moiety mimics the guanidine group in the dipeptide inhibitors for potential hydrogen-bonding interactions with the NOS active-site Glu592, which is conserved in all mammalian NOS isoforms. The pyrrolidine nitrogen mimics the α -amino group of dipeptide inhibitors and provides a positive charge next to the Glu592 in nNOS and close to another negatively charged residue, Asp597, which is Asn in eNOS. Therefore, nNOS has two negative charges in the active site compared to one in eNOS, and, as a result, nNOS provides better electrostatic stabilization to the positively charged inhibitors and is the primary reason why these inhibitors are selective for nNOS. An additional complication with the pyrrolidine inhibitors is that the binding orientation depends on the stereochemistry at the 3'- and 4'-positions of the pyrrolidine.^{20,21} The (3'S,4'S) inhibitors behave just like the dipeptide inhibitors, hydrogen-bonding with their 2-aminopyridine to the NOS active-site Glu residue, while the pyrrolidine nitrogen also interacts with this same Glu, as does the α -amino group of dipeptide inhibitors. We refer to this binding mode as the “normal” binding mode. However, the (3'R,4'R) inhibitors bind in a 180° flipped over mode, so that the 2-aminopyridine makes bifurcated hydrogen bonds with heme propionate D, and the hydrophobic tail binds above the heme next to the active-site Glu. We refer to this binding mode as the “flipped” binding mode. In the flipped binding mode there also is a new π -stacking interaction of the 2-aminopyridine with Tyr706. These two different binding modes are illustrated in Figure 2 for **2a** and **2b** bound to nNOS.

Although the (3'R,4'R) inhibitors show great potency ($K_i < 10$ nM) and excellent selectivity for nNOS over eNOS (>2500-fold) and iNOS (>700-fold) (Table 1), the positive charges derived from the side-chain basic groups dramatically impair

Table 1. Inhibition of NOS Isozymes by the Enantiomerically Pure Isomers of 1–3

compd	K_i (μ M) ^a			selectivity ^a	
	nNOS	eNOS	iNOS	n/e	n/i
1a	0.052	26.4	3.8	506	74
1b	0.005	20.3	3.9	3830	743
2a	0.116	26.2	7.5	226	65
2b	0.007	19.2	5.8	2667	806
(±)- 3	0.080	62.0	52.0	780	650

^an/e and n/i are the selectivity ratios of K_i for eNOS or iNOS to K_i for nNOS.

the ability of these inhibitors to penetrate the blood–brain barrier (BBB).²⁶ To improve the bioavailability of these inhibitors, two fluorines were further introduced to the benzylic position of the *m*-fluorophenylethyl tail of **2b** to lower the side-chain NH pK_a (to about 5.5). The nNOS cell-based assay indicated that compound **3** (Figure 1, IC₅₀ = 19 μ M in cell-based assay) crossed the cell membrane 2.5-fold better than racemic **1**.^{27,28} Computational studies indicate that the flipped mode binds more tightly as a result of better electrostatic interactions between the protein and inhibitor, because in the “normal” binding mode the aminopyridine is only partially protonated as a result of unfavorable electrostatic interactions between the aminopyridine and pyrrolidine N atoms.²⁰

Removal of the side-chain NH group would be the most direct strategy to circumvent the side-chain positive charge and further improve BBB permeability. Here, we report the results of a series of monocationic pyrrolidine-based analogues as nNOS inhibitors (Figure 3A). In addition, on the basis of the crystal structures of these inhibitors with nNOS, we carried out steered molecular dynamics (SMD) simulations, which provide valuable information about the ligand–enzyme interactions and




Figure 3. Target molecules synthesized and tested in this study.

the pharmacophoric requirements needed for the design of potent inhibitors.^{29–31} Finally, the derivatives with doubly substituted pyridine heads (Figure 3B) were made to validate the predictions of our simulations.

RESULTS AND DISCUSSION

Chemistry. Scheme 1 shows the synthetic route for target compounds 4–9. The synthesis of **12a** and **12b** was described previously.^{21,23} Single enantiomer **12a** or **12b** was treated with NaH, and the resulting anion was allowed to react with (*Z*)-(((4-bromobut-2-en-1-yl)oxy)methyl)benzene. Catalytic hydrogenation of the crude product then removed the benzyl protecting group and also reduced the double bond, giving high yields of purified alcohol **13a** or **13b**. The oxidation of **13a** and **13b** gave aldehydes **14a** and **14b**, respectively. Next, a Wittig reaction of the aldehydes with the corresponding phosphorus ylides allowed the isolation of intermediates **19a**, **19b**, and **20–22** in moderate yields. Finally, reduction of **19a**, **19b**, and **20–22** was performed to reduce the double bonds, followed by Boc deprotection to form the corresponding target products **4a**, **4b**, **6**, **8**, and **9**.


The bromination of **13b**, followed by nucleophilic substitution with 3-chloro-5-fluorophenol, provided intermediate **27**. The Boc protecting groups of **19a**, **19b**, and **27** were removed to generate inhibitors **5a**, **5b**, and **7**.

The synthetic route for **10** and **11** is shown in Scheme 2. Boc-protected 2-aminopyridine analogues **28** and **29** were treated with *n*-butyllithium and allowed to react with (*Z*)-(((4-bromobut-2-en-1-yl)oxy)(*tert*-butyl)dimethylsilane. The amino groups of the products were further protected with benzyl groups. The TBS protecting group was then removed, followed by bromination to generate intermediates **30** and **31**. Subsequently, nucleophilic substitution of alcohol **12b** with the allyl bromides gave the corresponding ethers. Debenzylation of the ethers with hydrogen gave **32** and **33**, in which the double bond was also reduced. Finally, removal of the Boc protecting group proceeded smoothly, giving high yields of the target products **10** and **11**.

In Vitro NOS Inhibition by 4–7. Table 2 shows the results of inhibition assays using purified NOS enzymes with 4–7.

(3′*R*,4′*R*) Inhibitors **4b** and **5b** exhibit much better nNOS inhibitory potency and selectivity over the other two NOS isozymes than the corresponding (3′*S*,4′*S*)-enantiomers **4a** and **5a**, respectively. Introduction of a trans double bond into (3′*S*,4′*S*)-**4a** (compound **5a**) results in a reduction in activity, whereas the potency increases a little by introduction of a trans double bond into (3′*R*,4′*R*)-**4b** (compound **5b**). Compared to the 3-fluorophenyl analogue **4b**, the double halo-substituted phenyl compound **6** exhibits 4-fold better inhibitory potency and selectivity for nNOS over eNOS. Structural optimization of **6** leads to the generation of 3-fluoro-5-chlorophenyl ether **7**, which exhibits 2-fold better inhibitory potency but 4-fold lower selectivity for nNOS over eNOS than **6**.

Crystallographic Studies of 4–7. To better understand the structure–activity relationships for 4–7, the crystal structures of nNOS complexed with these inhibitors were determined (Figure 4). Consistent with the binding preference of parent compound **2a**, the (3′*S*,4′*S*)-isomers **4a** and **5a** are found to bind in the normal binding mode with their aminopyridine moiety hydrogen-bonded to the side chain of Glu592 in nNOS (Figure 4A,C), and the pyrrolidine nitrogen also forms a hydrogen bond with Glu592. A water molecule provides a hydrogen-bonding bridge for the pyrrolidine N atom and the side chains of both Tyr588 and Asp597. The side chain beyond the ether O atom and the fluorophenyl end is disordered and only visible at low electron density contour levels. Surprisingly, (3′*R*,4′*R*)-isomers **4b** and **5b** break the rule of our previous pyrrolidine-based inhibitors. Despite their (3′*R*,4′*R*) stereochemistry, they exhibit the unexpected normal binding mode, similar to the conformation of the (3′*S*,4′*S*) enantiomers. The 2-aminopyridine moieties interact with Glu592, while the 3-fluorophenyl group extends out of the substrate catalytic site and points toward the entrance of the binding pocket (Figure 4B,D). The locations of the pyrrolidine rings of **4b** and **5b** are similar to that of **4a**. Although the pyrrolidine nitrogen can no longer directly hydrogen-bond to Glu592, it can still form a hydrogen bond with the same water molecule found in the **4a**-nNOS structure (Figure 4A) that bridges to a hydrogen-bond network with both Tyr588 and Asp597. However, the rest of both inhibitor molecules beyond

Scheme 1. Synthesis of 4–9^a


^aReagents and conditions: (a) (i) NaH, DMF, 0 °C, 3 h, (ii) 20 wt % Pd(OH)₂/C, H₂, EtOH, 60 °C, 36 h, 91–94%; (b) Dess–Martin periodinane, CH₂Cl₂, rt, 18 h, 89–92%; (c) LHMDS, –78 °C to rt, THF, 8 h; (d) 10% Pd/C, H₂, MeOH, rt, 12 h; (e) 3 N HCl/MeOH, rt, 24 h, 47–69% for three steps; (f) 3 N HCl/MeOH, rt, 24 h, 90–93%; (g) (i) PPh₃, CBr₄, CH₂Cl₂, 0 °C, 3 h, (ii) 3-chloro-5-fluorophenol, K₂CO₃, acetone, reflux, 12 h, quantitative; (h) 3 N HCl/MeOH, rt, 24 h, quantitative.

the ether oxygen is poorly defined and can only be modeled on the basis of partial electron density at low contour levels. In chain B the position of the fluorophenyl tail of **4b** is closer to heme propionate D, with the Tyr706 side chain adopting the rotamer associated with the flipped binding mode (see Supporting Information (SI) Figure S1A). More interestingly, **5b** shows alternate binding conformations in chain B and binds mostly (~70%) in the normal mode, but with a small population (~30%) in the flipped mode (Figure S1B). The crystallographic results indicate that both binding modes are almost isoenergetic, which means that small perturbations can apparently change the ligand binding conformation without significantly changing stability. Similar observations have been made for inhibitor binding to elastase.³²

Despite their high structural similarity to **4b**, both of the 3-fluoro-5-chlorophenyl analogues **6** and **7** adopt the flipped binding mode as expected from their (3'R,4'R) chirality (Figure

5). The aminopyridine makes bifurcated hydrogen bonds with heme propionate D. The pyrrolidine N atom hydrogen-bonds to both heme propionate A and H₄B. The flexible linker extending from the pyrrolidine brings the 3-fluoro-5-chlorophenyl ring to the substrate catalytic site to form π -stacking interactions with the heme. However, the larger size of the 3-fluoro-5-chlorophenyl group forces Glu592 into an alternate rotamer position. This alternate Glu side-chain position also was observed in the eNOS-2-bromo-7-nitroindazole complex.³³ Overall, one extra ether oxygen in **7** does not change its binding conformation much from that seen for **6**, which is consistent with the similar potency shared by the two inhibitors (Table 2).

Docking and Steered Molecular Dynamics Simulations. The normal binding mode of (3'R,4'R)-isomers **4b** and **5b** was completely unexpected because it breaks the precedent that had been established by many crystal structures, demonstrating that the (3'R,4'R)-pyrrolidine analogues adopt

Scheme 2. Synthesis of 10 and 11^a

^aReagents and conditions: (a) (i) *n*-BuLi, THF, -78 °C to rt, 2 h, (ii) NaH, DMF, 0 °C, 3 h, (iii) TBAF, DMF/THF, 0 °C, 2 h, (iv) PPh₃, CBr₄, CH₂Cl₂, 0 °C, 3 h, 26–43%; (b) (i) NaH, DMF, 0 °C, 3 h, (ii) 20 wt % Pd(OH)₂/C, H₂, EtOH, 60 °C, 36 h, 84–89%; (c) 3 N HCl/MeOH, rt, 24 h, 89–94%.

Table 2. Inhibition of NOS Isozymes by Synthetic Compounds 4–7

compd	K_i (μ M) ^a			selectivity ^b	
	nNOS	eNOS	iNOS	n/e	n/i
4a	9.057	34.0	468.5	4	52
4b	0.922	33.8	83.8	37	91
5a	15.402	69.0	133.8	4	9
5b	0.637	77.0	35.1	121	55
6	0.230	35.6	106.0	155	461
7	0.117	4.4	12.4	37	106

^aThe apparent K_i values are represented as the mean of two or more independent experiments performed in duplicate with five or six data points each. ^bn/e and n/i are the selectivity ratios of K_i for eNOS or iNOS to K_i for nNOS.

the flipped binding mode. Only one bioisosteric change (replacing the side-chain NH by CH₂) from parent compound **2b** both dramatically affects inhibitory potency and radically changes the binding mode. Clearly, the chemical nature of the side chain and the tail end affects the inhibitor binding mode, but how? What kind of inhibitor–enzyme interactions, other than chirality, determine the binding mode? To study the molecular interactions involved in formation of the ligand–enzyme complex and to answer these questions, we carried out computational studies combining docking, equilibrium, and SMD simulations.

The two most populated clusters of docking conformations were obtained by using different nNOS receptors. One, in which **2a** is bound, exhibits the normal binding mode, and the other, with **2b** bound, exhibits the flipped binding mode. After **2a** and **2b** were removed, the receptors were used to dock **4b**, which gives **4b**-nNOS complexes corresponding to the normal and flipped poses, respectively (Figure 6). Hereafter, the normal and flipped docking poses are referred to as **4b**-N and **4b**-F, respectively. Consistent with the binding preference of **4b** in the crystal structure, the aminopyridine moiety of docking pose **4b**-N establishes hydrogen-bonding interactions with Glu592. Its pyrrolidine nitrogen also interacts with Glu592 and is part of a water-mediated hydrogen-bonding network involving Tyr588 and Asp597. In contrast, the aminopyridine group in **4b**-F makes bifurcated hydrogen bonds with the propionate of pyrrole ring D. Tyr706 rotates farther out, without making an optimized π -stacking interaction with the

aminopyridine ring. The pyrrolidine N atom in **4b**-F makes favorable hydrogen bonds with propionate A, while the hydrogen bond with the O4 atom of H₄B is broken.

The crystallographically flipped pose of **2b**, crystallographically normal pose of **4b**, and flipped docking pose **4b**-F were subsequently submitted to 5 ns equilibrium molecular dynamics (MD) simulations. The root-mean-square deviation (rmsd) values of all atoms and the C $_{\alpha}$ atoms of nNOS as a function of time for the 5 ns MD simulation are shown in SI Figure S2, suggesting the whole structure has been equilibrated after about 1.5 ns.

The rmsd values of ligands **2b**, **4b**, and **4b**-F versus simulation time are shown in Figure 7A. These results indicate that both **4b** and **4b**-F are more flexible than **2b**. The structure of **2b** appears to have been stabilized, with the rmsd value of ~ 1 Å after ~ 500 ps of simulation, while the structures of **4b** and **4b**-F are stabilized after ~ 1500 ps of simulation, with rmsd values of ~ 2 and ~ 3 Å, respectively. To further probe the differences among the moieties located in the substrate catalytic pocket above the heme, center–center distances between the Fe atom of the heme co-factor and the aromatic group of the ligands were monitored during the MD simulation, and the results are shown in Figure 7B. During the simulation, the aromatic heads (aminopyridine) of **2b** and **4b** vibrate slightly in the catalytic pocket, their distances to heme-Fe being relatively stable at ~ 3.5 Å. The profile of the center–center distance between the heme-Fe and the aromatic tail (fluorophenyl) of **4b**-F forms the first platform from 0 to 380 ps at ~ 3.3 Å. The distance then sharply increases to ~ 4.5 Å and forms a short platform from 380 to 1100 ps, followed by a long platform after 1000 ps at ~ 5 Å.

To understand the interactions between nNOS and the ligands, the direct hydrogen bonds were analyzed. Compound **2b** can potentially form more hydrogen bonds with the enzyme than **4b** and **4b**-F. Figure 7C shows the statistics of hydrogen bonds formed every 4 ps. Statistical analysis shows that the hydrogen bonds of **2b** and **4b**-F with the highest occurrence frequency involve heme propionate A, heme propionate D, and H₄B. For the **4b**-nNOS system, the dominant hydrogen bonds were formed by Glu592. In our simulation, Glu592 is a flexible residue, which can swing toward the side-chain N atom of **2b**, forming a salt bridge or hydrogen bond, and stabilize **2b** (Figure 8A). Both the hydrogen bond numbers and the hydrophobic interaction numbers for **2b** and **4b** are relatively




Figure 4. Crystallographic binding conformations of **4a** (A), **4b** (B), **5a** (C), and **5b** (D) with rat nNOS. The omit $F_o - F_c$ electron density maps for the inhibitors are shown at 2.5σ contour level. Major hydrogen bonds are depicted with dashed lines. Atom color scheme: oxygen, red; nitrogen, blue; sulfur, yellow; fluorine, light cyan; chlorine, green.




Figure 5. Crystallographic binding conformation of **6** (A) and **7** (B) with rat nNOS. The omit $F_o - F_c$ electron density maps for inhibitors are shown at 2.5σ contour level. Major hydrogen bonds are depicted with dashed lines. The atom color scheme from Figure 4 is used.

stable during the simulation, while those for **4b-F** decrease gradually from 4 and 35 to 2 and 20 before 1000 ps, respectively, and then stabilize at 3–4 and ~ 20 after 1100 ps. This is in good agreement with the variation of the center–center distance between heme-Fe and the aromatic fluoro-phenyl tail of **4b-F**.

Figure 8 displays snapshots of the structures of ligand–nNOS complexes at 5000 ps. Both the **2b**–nNOS X-ray crystal structure and the dynamics simulation demonstrate the importance of the presence of water molecules in ligand binding to nNOS. A water molecule bridging the side-chain

amine nitrogen in **2b** with heme propionate D was seen during the entire simulation (Figure 8A). The water molecule and the atoms between the O atom and N atom in the side chain of **2b** form a rigid five-membered ring structure, which greatly stabilizes the flipped binding conformation of **2b**. In contrast to **2b**, no water bridge between the O atom of **4b-F** (lack of the side-chain N atom) and heme propionate D was detected in the simulation.

To investigate the molecular mechanism, at the atomic level, of a ligand leaving the binding pocket of nNOS, we performed SMD simulations, which can reveal features characteristic of the




Figure 6. Docking conformation of **4b** with different rat nNOS crystal structures: (A) **4b-N**, in which **2a-nNOS** complex (PDB ID 3NLK) was used as the receptor, and (B) **4b-F**, in which **2b-nNOS** complex (PDB ID 3NLM) was used as the receptor.




Figure 7. (A) Time dependence of the rmsd. (B) Distance between the heme-Fe and the center of the aromatic head. (C) Numbers for the direct hydrogen bonds. (D) Numbers for hydrophobic interactions in the equilibrium MD simulations. All curves were obtained over 4 ps intervals.




Figure 8. Snapshots of **2b** (A), **4b** (B), and **4b-F** (C) isolated from the equilibrium MD at 5000 ps. The dashed lines represent hydrogen bonds and a water bridge. The water molecule in (A) is shown as a red sphere. Residues around the ligand within 8 Å were selected to show the surface.

reverse process of binding. The profiles of the force exerted on the system to encourage the unbinding of the ligands along a carefully predefined reaction coordinate are shown in Figure 9A (see also the Experimental Section and SI Figure S3 for further

details). During the unbinding of **2b**, the concerted rupture of the anchoring interactions (mainly electrostatic interactions, hydrogen bonds, and hydrophobic interactions) between nNOS and **2b** defines the primary event with an unfolding




Figure 9. Plot of the rupture force (A), number of direct hydrogen bonds (B), and number of hydrophobic interactions (HI) (C) versus time in the equilibrium MD simulations. All curves were obtained over 4 ps intervals.




Figure 10. Snapshots of **2b** (A), **4b** (B), and **4b-F** (C) isolated from the SMD before and after dissociation. The dashed lines represent hydrogen bonds and the water bridge. The water molecule in (A) is shown as a red ball. Residues around the ligand within 8 Å were selected to show the surface.

force of ~ 77 kJ/(mol·Å) (Figure 9A), significantly higher than the 58.3 and 50.1 kJ/(mol·Å) measured for **4b** and **4b-F**, respectively, at the same pulling force constant. In particular, the unbinding is controlled by a breakup in the charge-reinforced hydrogen-bonding network between the ligand pyrrolidine N atom and heme propionate A. The pulling

force profile of **4b** is similar to that of **2b**; the forces increase in the beginning of ligand unbinding and reach a maximum around 2500 ps, followed by a return to zero. Notably, both the responses of **2b** and **4b** to the pulling force evolve in two distinct stages (Figure 9A): (i) from 0 to 2600 ps (**4b**) or 3200 ps (**2b**), a buildup of force during which hydrogen bonds

between the ligands with heme propionate A, heme propionate D, and Glu592 are ruptured; (ii) after those times, the ligands are pulled out of the binding pocket.

Interestingly, **4b-F** suffers a three-state pathway for forced unbinding: an intermediate state is maintained from 2150 to 2350 ps between the maximum rupture force and breakdown of the primary unbinding barrier (Figure 9A). From 2140 to 2260 ps, the hydrophobic interactions between **4b-F** and nNOS are broken, while the hydrogen-bonding number remains relatively constant.

Ligands in nNOS are shown in their bound states before and after dissociation in Figure 10. A key observation during this time is that **4b-F** curls up within the binding pocket. This curling, clearly discernible in Figure 10C, is the result of the rupture of hydrophobic interactions between the fluorobenzene moiety and the substrate binding pocket, while most hydrogen bonds between **4b-F** and heme propionate D remain intact (Figure 9B,C). The curling then orients the fluorophenyl end of **4b-F** into a position that permits it to easily dissociate from the binding pocket. These results clearly indicate the instability of the fluorophenyl end located in the catalytic pocket and favor **4b** in a normal binding mode.

What are the determining factors that result in a normal binding pose for the (3*R*,4*R*)-pyrrolidine analogue **4b**? The SMD simulation calculations provide some clues. The structural features of **4b** have the potential to make it bind to nNOS with either the normal or flipped pose. We thought the hydrogen bonds from the aminopyridine and pyrrolidine to the surrounding protein would be the key factors that determine which way the inhibitors bind.

However, the chemical nature of the side chain and the aromatic end group also matters. SMD simulation results shown in Figure 10 indicate that **2b** in its flipped binding mode utilizes its side-chain nitrogen to interact with a water molecule that bridges in between **2b** and heme propionate D. This N atom also interacts with the Glu592 side chain for another hydrogen bond. The side chain and the fluorophenyl end of **4b-F** are extremely unstable because of the lack of this side-chain N atom, resulting in a curling of the tail prior to its much easier dissociation from the substrate catalytic pocket. Therefore, **4b** prefers to adopt the normal binding mode. Comparisons of the force profiles for **4b** and **2b** (Figure 9A) show that the binding affinity of **4b** is considerably weaker than that for **2b**. This is understandable for the following reasons: (i) in the normal binding mode **4b** has fewer hydrogen bonds, hydrophobic interactions, and electrostatic interactions than **2b** in a flipped mode; (ii) the side chain without the amino N atom causes the fluorophenyl moiety of **4b** to vibrate more vigorously in the pocket surrounded by Met336, Leu337, and Tyr706 because of no hydrogen-bonding possibilities; (iii) the orientation of the pyrrolidine ring of **4b** in the normal mode makes it impossible to form a hydrogen bond to Glu592.

These results show that SMD simulations can be used to guide the development of better nNOS inhibitors. As shown in Figure 11, the substrate binding pocket (region A) should be occupied by an aromatic ring, which not only stacks with the heme but should also interact with Glu592 for additional stability. This implies that introducing one or more heteroatoms embedded in the aromatic ring or linker chain should be favorable. In addition, an anchoring part that can interact with heme propionate A or Asp597 should be located in region B. This part functions to anchor the ligand in the substrate catalytic pocket and to position the tail aromatic ring




Figure 11. Pharmacophoric requirements needed for the design of potent nNOS inhibitors.

to region A appropriately. Moreover, an aminopyridine fragment in region C is favorable to enhance the affinity through the bifurcated hydrogen bonds with heme propionate D and the π -stacking interaction with Tyr706.

One final question to address is why **6** and **7** bind in the flipped mode, even though both **6** and **7** are close analogues of **4b**, which binds in the normal orientation. The only difference between **4b** and **6** is the additional Cl atom added to the fluorophenyl group of **4a**. The bulkiness of the doubly-substituted phenyl group forces the Glu592 side chain to adopt a different rotamer, resulting in less steric clashes between the chlorofluorophenyl group and Glu592. In addition, the second halogen atom increases the hydrophobic character of the protein–ligand interface within the active-site pocket.^{34,35} It also reduces the electron density of the aromatic ring, allowing more favorable parallel π -stacking interactions between the chlorofluorophenyl tail and the heme.^{36,37} Both increased interactions enhance the binding affinity of the tail phenyl group to region A, thus tipping the balance in favor of the flipped orientation.

New Analogue Design, NOS Inhibition, and Crystallographic Analysis of 8–11. As mentioned above, the simulation results imply that one or more heteroatoms embedded in the aromatic ring or linker chain should favorably stabilize the ligand by providing an additional hydrogen bond with the protein. A pyridine ring is a good candidate to replace the fluorophenyl moiety because it has the potential to form hydrogen-bonding interactions with Glu592 and importantly, it would not be protonated under physiological conditions.

Both the activities and the crystal structures of double-headed pyridine analogues **8–11** correlate well with the insights gained from the above MD simulations. The corresponding K_i values and nNOS selectivity ratios of **8–11** are shown in Table 3. The enzyme assay results indicate that the tested compounds are potent and selective inhibitors toward nNOS, with K_i values in the low nanomolar range. With the aim of investigating the effect of 4-methyl and 6-amino groups on the pyridine head, we synthesized compounds **9–11**. Each of the substitutions increases the potency of the nNOS inhibitor relative to that of parent compound **8**. Compounds **9** and **10** have the greatest combined potency for nNOS and selectivity over eNOS and iNOS of any of the monocationic pyrrolidine-based nNOS inhibitors reported to date. Compound **11**, with both 4-methyl and 6-amino groups on the pyridine head, maintains an nNOS inhibitory activity comparable to those of **9** and **10**, but its selectivities over

Table 3. Inhibition of NOS Isozymes by Synthetic Compounds 8–11

compd	K_i (μM) ^a			selectivity ^b	
	nNOS	eNOS	iNOS	n/e	n/i
8	0.074	148.9	9.8	2012	132
9	0.031	45.2	17.3	1459	558
10	0.030	33.5	18.6	1117	619
11	0.038	26.1	6.5	687	172

^aThe apparent K_i values are represented as the mean of two or more independent experiments performed in duplicate with five or six data points each. ^bn/e and n/i are the selectivity ratios of K_i for eNOS or iNOS to K_i for nNOS.

eNOS (687-fold) and iNOS (172-fold) are decreased relative to those of 8–10.

Crystal structures of nNOS complexed with 8 and 9 show that these inhibitors adopt the flipped binding mode again (Figure 12A,B). Their pyridine heads interact with active-site Glu592, which stabilizes binding. The extra methyl group in the pyridine ring of 9 further helps to tightly position the ring by providing additional hydrophobic contacts with the protein. The positively charged N atoms in the pyrrolidine rings interact with heme propionate A, and the aminopyridine heads extend out of the active site, where they form bifurcated salt bridges with heme propionate D. The presence of the pyridine N atom

strongly stabilizes inhibitor binding, which confirms the predictions from our MD simulations.

Addition of the 6-amino group to the pyridine ring in 10 and 11 further enforces the hydrogen-bonding interaction between the inhibitor and Glu592, as shown in Figure 12C,D, although it does not necessarily improve the potency (Table 3). These two compounds are double-headed aminopyridine inhibitors; however, they bind to the other two isoforms more tightly as well, thus lowering the selectivity.

The two best inhibitors, 9 and 10, were further tested for their potency in a cell-based nNOS assay, which can provide information about their membrane permeability.³⁸ As shown in Figure 13, the IC_{50} value for 9 is 20 μM , very similar to that of the difluorinated analogue 3 (19 μM). Remarkably, compound 10 is 2.7 times more potent than 3, which demonstrates a successful improvement in membrane permeability for the pyrrolidine-based nNOS inhibitors and validates our approach toward eliminating the positively charged amines in the scaffold.

Compared to their *in vitro* activities, the potencies of these pyrrolidine-based analogues in the cell-based assay are weaker, which may relate to both their membrane permeability and pharmacokinetic properties. Besides their potential affinity for one of the active efflux transporters (e.g., *p*-glycoprotein), metabolic properties also play important roles.³⁹ Metabolism may make the inhibitors ineffective or decompose them, thus weakening their cellular activities. The metabolic stability of 10




Figure 12. Crystallographic binding conformation of 8 (A), 9 (B), 10 (C), and 11 (D) with rat nNOS. The omit $F_o - F_c$ electron density maps for inhibitors are shown at 2.5σ contour level. Major hydrogen bonds are depicted with dashed lines. The atom color scheme shown in Figure 4 is used.




Figure 13. Dose–response curves and IC_{50} values for **9** (A) and **10** (B) in a cell-based nNOS assay. Curves represent the average of three separate experiments.

can be compared to that of (*R,R*)-**3**. The *in vitro* metabolic rate was 0.05 (nmol/min/mg protein) for (*R,R*)-**3** and 0.02 (nmol/(min·mg) protein) for **10**; 69% of (*R,R*)-**3** and 85% of **10** remain after 60 min in the presence of NADPH. It is apparent that **10** has improved metabolic stability over (*R,R*)-**3**.

CONCLUSIONS

In summary, we have described an interdisciplinary study of a series of selective monocationic inhibitors of nNOS. Three stages of investigation allowed for the following conclusions:

(i) The potencies and selectivities of a series of monocationic nNOS inhibitors decreased sharply, even with the small modification of removing the side-chain amino nitrogen compared to the potent and selective parent compound. The crystal structures revealed that they adopt an unexpected normal binding mode.

(ii) To investigate the underlying binding characteristics and reveal the important potential pharmacophoric features of the nNOS inhibitors, we carried out computational studies combining molecular docking, equilibrium, and SMD simulations. These computational results suggest that one or more heteroatoms embedded in the aromatic head or linker chain should be favorable to stabilize the ligand and allow it to tightly occupy the substrate binding pocket.

(iii) The enzyme inhibition results of four double-headed pyridine analogues, in conjunction with their crystal structures, confirm the computational insights very well. Remarkably, **9** and **10** are the most combined potent and selective monocationic pyrrolidine-based nNOS inhibitors reported to date. Moreover, **10** has improved membrane permeability and serves as a lead molecule for further development.

(iv) Both computational and experimental insights from this study can be utilized to design even more effective nNOS inhibitors.

EXPERIMENTAL SECTION

Organic Synthesis. All reagents were purchased from Sigma-Aldrich, Alfa Aesar, or TCI and were used without further purification. Analytical thin-layer chromatography was visualized by ultraviolet, ninhydrin, or phosphomolybdic acid (PMA). Flash column chromatography was carried out under a positive pressure of air. ^1H NMR and ^{13}C NMR spectra were recorded on 500 and 125 MHz spectrometers, respectively. High-resolution mass spectra were measured by liquid chromatography/time-of-flight mass spectrometry (LC-TOF). For synthetic details, see the SI.

Molecular Docking. AutoDock 4.2 was used to predict the potential binding between **4b** and nNOS.^{40,41} The crystal structures of rat nNOS oxygenase domain in complex with **2a** and **2b** (PDB entries 3NLK and 3NLM) were used as the receptors. The ligand and solvent molecules were removed from the crystal structures to obtain the

docking grid, and the active site was defined using AutoGrid. The grid size was set to $60 \times 60 \times 60$ points with grid spacing of 0.375 Å. The grid box was centered on the ligand from the corresponding crystal structure complexes. The Lamarckian genetic algorithm was used for docking with the following settings: a maximum number of 2,500,000 energy evaluations, an initial population of 150 randomly placed individuals, a maximum number of 27 000 generations, a mutation rate of 0.02, a crossover rate of 0.80, and an elitism value (number of top individuals that automatically survive) of 1. The structure of **4b** was built and geometry optimized using the molecular modeling suite of programs Sybyl-X 1.2 (Tripos International, St. Louis, MO). The ligand was fully optimized inside the binding site during the docking simulations. Finally, the conformation with the lowest predicted binding free energy of the most frequently occurring binding modes in the nNOS active pocket was selected.

MD Simulation. The models used in the present study were based on the X-ray crystal structures of the corresponding nNOS–ligand complexes. The coordinates of the missing residues (339–349 in chain A and 339–347 in chain B) were added according to the intact X-ray crystal structures of nNOS (PDB entry code 1ZVL) using the molecular modeling software Sybyl-X 1.2. The repaired residues were subjected to energy minimization in Sybyl-X 1.2 using the steepest descent method up to a gradient tolerance of 0.05 kcal/(mol·Å) to relieve possible steric clashes and overlaps of side chains, with the rest of the complex fixed. The ionization states of the residues were determined by the Web-based program H++ (<http://biophysics.cs.vt.edu/H++>).^{42,43} All of the simulations were carried out using the GROMACS 4.5.3 package with an identical protocol.^{44,45} The ligands were extracted from the corresponding complex crystal structures or docking results. The secondary amines were modeled as charged. Topology files and parameters for the ligands were generated using the AmberTools 1.5 package (<http://ambermd.org/>). A modification of the AMBER03 force field and the generalized AMBER force field were applied for the proteins and ligands, respectively.^{46,47} The reported AMBER force field parameters for the heme and Cys-Fe bond were adopted.⁴⁷ TIP3P water molecules were added in cuboid periodic boxes, which were $120 \text{ \AA} \times 110 \text{ \AA} \times 120 \text{ \AA}$.⁴⁸ To ensure overall neutrality of the system, appropriate Na^+ and Cl^- were added at physiological concentration in the box.

All covalent bonds to H atoms were constrained using the linear constraint solver method. Electrostatic interactions were calculated using the particle mesh Ewald algorithm.^{49,50} Periodic boundary conditions were applied to avoid edge effects in all calculations. Before the MD run, the energy of these complexes was minimized to remove conflicting contacts. The systems were then heated gradually from 0 to 310 K. After a 50 ps equilibration of water, two 250 ps equilibrations of the system were carried out with the restriction of main chain and carbon α -helix, respectively. Finally, 5 ns simulations were carried out, with coordinates saved every 2 ps during the entire process. Afterward, selective structures from the end of these trajectories were used as starting configurations for single-molecule pulling simulations. Ligand in the active site of chain A was pulled out along the previously defined axis that extends from heme-CAB atom in chain A to the center of mass (COM) of atomic group of Trp711-CE2 in chain A and Trp306-

Table 4. Crystallographic Data Collection and Refinement Statistics

	nNOS-4a	nNOS-4b	nNOS-5a	nNOS-5b	nNOS-6	nNOS-7	nNOS-8	nNOS-9	nNOS-10	nNOS-11
	Data Collection									
PDB code	3UFO	3UFP	3UFQ	3UFR	3UFS	3UFT	3UFU	3UFV	3UFW	4EUX
space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁
cell dimens <i>a</i> , <i>b</i> , <i>c</i> (Å)	52.2, 111.6, 165.0	52.0, 110.9, 164.5	52.1, 111.0, 164.5	51.9, 111.3, 164.5	51.8, 111.3, 164.2	51.8, 111.2, 164.1	52.1, 110.8, 164.4	51.7, 110.2, 164.3	51.9, 111.2, 164.1	52.0, 111.2, 164.3
resolution (Å)	2.18 (2.22– 2.18)	2.10 (2.21– 2.10)	2.05 (2.09– 2.05)	2.10 (2.14– 2.10)	1.97 (2.00– 1.97)	2.08 (2.12–2.08)	1.89 (1.92– 1.89)	2.08 (2.12– 2.08)	2.00 (2.03– 2.00)	2.14 (2.18– 2.14)
<i>R</i> _{sym} / <i>R</i> _{merge}	0.079/0.570	0.095/0.489	0.067/0.536	0.070/0.656	0.053/0.460	0.084/0.656	0.056/0.546	0.055/0.662	0.077/0.654	0.096/0.630
<i>I</i> / σ <i>I</i>	22.5(2.0)	5.4(1.6) ^b	24.5(1.9)	24.1(2.1)	31.9(2.4)	29.8(2.1)	22.7(1.9)	24.3(2.2)	24.5(1.6)	20.4(1.8)
no. unique reflns	50 641	56 388	59 092	55 153	67 604	57 805	75 429	55 597	64 761	52 877
completeness (%)	97.8 (94.6)	99.7 (100.0)	98.4 (94.5)	97.2 (100.0)	98.6 (83.0)	99.6 (99.7)	97.2 (96.8)	96.7 (96.2)	99.4 (99.9)	99.3 (100.0)
redundancy	4.1 (4.1)	3.9 (3.9)	3.7 (3.7)	4.1 (4.1)	4.0 (3.7)	4.8 (3.9)	4.1 (4.2)	3.9 (3.9)	4.0 (3.9)	3.9 (4.0)
	Refinement									
resolution (Å)	2.18	2.10	2.06	2.10	1.97	2.08	1.89	2.08	2.00	2.14
no. reflns used	47 872	53 442	55 921	52 229	64 012	54 727	71 429	52 658	61 504	50 181
<i>R</i> _{work} / <i>R</i> _{free} ^a	0.198/0.254	0.208/0.262	0.190/0.231	0.199/0.249	0.193/0.233	0.206/0.260	0.175/0.209	0.175/0.218	0.196/0.244	0.180/0.228
no. of atoms										
protein	6678	6660	6660	6669	6671	6660	6681	6690	6665	6671
ligand/ion	196	185	185	209	187	187	183	185	185	185
water	195	259	270	220	284	167	367	325	252	268
rms deviations										
bond lengths (Å)	0.016	0.015	0.015	0.016	0.015	0.019	0.014	0.015	0.015	0.011
bond angles (deg)	1.589	1.565	1.317	1.640	1.485	1.865	1.421	1.485	1.513	1.981

^a*R*_{free} was calculated with the 5% of reflections set aside throughout the refinement. The set of reflections for the *R*_{free} calculation were kept the same for all data sets according to those used in the data of the starting model (1OM4). ^bThis data set was processed with MOSFLM. All others were processed with HKL2000.

CE2 in chain B. Chain A was used as an immobile reference for the COM pulling simulation. It should be emphasized that the pulling velocity is an important parameter in the COM pulling simulations.^{51,52} The simulations at higher pulling velocity may lead to substantial nonequilibrium effects. The low-velocity pulling simulations that were carried out on a millisecond time scale can overcome these disadvantages; however, the corresponding computational cost will be very expensive. To find an appropriate simulation velocity, several pulling simulations were carried out at different pulling velocities. The simulation results are listed in SI Figures S2 and S3. Finally, the SMD simulations with a pulling rate of 0.01 Å/ps and a force constant of 2.5 kJ/(mol·Å²) were selected. LIGPLOT 5.0.4 was used to analyze the hydrogen bonds and hydrophobic interactions between nNOS and the ligands in the MD simulation trajectories.⁵³ Figures 2, 4–6, 8, and 10–12 were prepared with PyMol (<http://www.pymol.org>).

Enzyme Assays. The three isozymes, rat nNOS, murine macrophage iNOS, and bovine eNOS, were recombinant enzymes, overexpressed (in *E. coli*) and isolated as reported.^{54–56} IC₅₀ values for inhibitors 4–11 were measured for the three different isoforms of NOS using L-arginine as a substrate. The formation of NO was measured using the hemoglobin capture assay described previously.⁵⁷ All NOS isozymes were assayed using a Synergy H1 Hybrid Multi-Mode Microplate Reader (BioTek Instruments, Inc.) at 37 °C in a 100 mM HEPES buffer (pH 7.4) containing 10 μM L-arginine, 0.83 mM CaCl₂, 320 units/mL calmodulin, 100 μM NADPH, 10 μM H₂B, and 3.0 μM oxyhemoglobin (for iNOS assays, no Ca²⁺ and calmodulin was added). The assay was initiated by the addition of enzyme, and the initial rates of the enzymatic reactions were determined by monitoring the formation of methemoglobin complex at 401 nm for 60 s. The apparent *K*_i values were obtained by measuring the percent enzyme inhibition in the presence of 10 μM L-arginine with at least five concentrations of inhibitor. The parameters of the following inhibition equation were fitted to the initial velocity data: % inhibition = 100[I]/{[I] + *K*_i(1 + [S]/*K*_m)}. *K*_m values for L-arginine were 1.3 (nNOS), 8.2 (iNOS), and 1.7 μM (eNOS). The selectivity of an inhibitor was defined as the ratio of the respective *K*_i values.

Cell-Based nNOS Inhibition Assay. HEK293t cells stably transfected with rat nNOS were cultured as previously described.³⁸ The nNOS inhibition assay was performed as previously reported,³⁸ with the following modifications: assays were performed in 96-well plates with a total volume of 100 μL, and 10 μM A23187 (Sigma-Aldrich, St Louis, MO) (added as 100× stock in 50% DMSO) was used in place of 5 μM. Eight concentrations of each inhibitor were tested, in at least triplicate wells. All inhibitors reported here were assayed within the same experiment to ensure consistencies in cell concentration and passage number. The entire assay was repeated at least three times for each inhibitor, and the IC₅₀ values were averaged. Cells were plated in the 96-well plates 24 h before activation at a concentration of approximately 8.5 × 10⁶ cells/mL, which resulted in 80–90% confluency. After 6 h of A23187 activation (in the presence or absence of inhibitor, which was added 30 min before activation), 50 μL aliquots of the media were removed from the wells. Nitrite production was quantified using Griess reagent and measuring absorbance at 540 nm.

Pharmacokinetic Data. All pharmacokinetic results were obtained by LC/MS/MS analysis in the DMPK group, Sai Advantium Pharma Ltd., Pune, India.

Inhibitor Complex Crystal Preparation. The nNOS heme domain proteins used for crystallographic studies were produced by limited trypsin digest from the corresponding full length enzymes and further purified through a Superdex 200 gel filtration column (GE Healthcare) as described previously.⁵⁸ The enzyme–inhibitor complex crystals were obtained by soaking, rather than co-crystallization, as reported in the earlier structural work.⁵⁹ The nNOS heme domain at 7–9 mg/mL containing 20 mM histidine was used for the sitting drop vapor diffusion crystallization setup under the conditions reported before.⁵⁸ Fresh crystals (1–2 days old) were first passed stepwise through cryo-protectant solutions as described⁵⁸ and then soaked with 10 mM inhibitor for 4–6 h at 4 °C before being mounted on nylon loops and flash-cooled by plunging into liquid nitrogen.

X-ray Diffraction Data Collection, Processing, and Structure Refinement. The cryogenic (100 K) X-ray diffraction data were collected remotely at various beamlines at Stanford Synchrotron

Radiation Lightsource or Advanced Light Source through the data collection control software Blu-Ice⁶⁰ and a crystal mounting robot. Raw data frames were indexed, integrated, and scaled using HKL2000.⁶¹ The binding of inhibitors was detected by the initial difference Fourier maps calculated with REFMAC.⁶² The inhibitor molecules were then modeled in COOT⁶³ and refined using REFMAC. Water molecules were added in REFMAC and checked by COOT. The TLS⁶⁴ protocol was implemented in the final stage of refinements with each subunit as one TLS group. The omit $F_o - F_c$ density maps were calculated by repeating the last round of TLS refinement with inhibitor coordinates removed from the input PDB file to generate the coefficients DELFWT and SIGDELFWT. The refined structures were validated in COOT before deposition in the RCSB protein data bank. The crystallographic data collection and structure refinement statistics are summarized in Table 4 with PDB accession codes included.

■ ASSOCIATED CONTENT

● Supporting Information

Details of chemical synthesis, alternate crystallographic binding conformation of **4b** and **5b** in chain B of rat nNOS, rupture force versus time in the process of **2b** leaving the nNOS binding gorge at different pulling force constant and pulling rates, time dependence of the rmsd of the ligand–nNOS complex for the all atoms and C^α in the equilibrium MD simulation, and complete spectroscopic data of compounds **4**–**11**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

poulos@uci.edu; Agman@chem.northwestern.edu

Present Address

[‡]Department of Chemistry, University of Utah, Salt Lake City, UT 84112-0850

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors are grateful for financial support from the National Institutes of Health (GM049725 to RBS and GM057353 to TLP). We thank Dr. Bettie Sue Siler Masters (NIH grant GM52419, with whose laboratory P.M. and L.J.R. are affiliated). B.S.S.M. also acknowledges the Welch Foundation for a Robert A. Welch Distinguished Professorship in Chemistry (AQ0012). P.M. is supported by grant 0021620849 from MSMT of the Czech Republic. We also thank the beamline staff at SSRL and ALS for their assistance during the remote X-ray diffraction data collections.

■ REFERENCES

- (1) Vallance, P.; Leiper, J. *Nat. Rev. Drug Discovery* **2002**, *1*, 939–950.
- (2) Stuehr, D. J. *J. Nutr.* **2004**, *134*, 2748s–2751s.
- (3) Rosen, G. M.; Tsai, P.; Pou, S. *Chem. Rev.* **2002**, *102*, 1191–1199.
- (4) Granik, V. G.; Grigor'ev, N. A. *Russ. Chem. Bull.* **2002**, *51*, 1973–1995.
- (5) Alderton, W. K.; Cooper, C. E.; Knowles, R. G. *Biochem. J.* **2001**, *357*, 593–615.
- (6) Li, H. Y.; Poulos, T. L. *J. Inorg. Biochem.* **2005**, *99*, 293–305.
- (7) Olesen, J. *Neurotherapeutics* **2010**, *7*, 183–190.
- (8) Reif, D. W.; McCarthy, D. J.; Cregan, E.; MacDonald, J. E. *Free Radic. Biol. Med.* **2000**, *28*, 1470–1477.
- (9) Villanueva, C.; Giulivi, C. *Free Radic. Biol. Med.* **2010**, *49*, 307–316.

- (10) Aquilano, K.; Baldelli, S.; Rotilio, G.; Ciriolo, M. R. *Neurochem. Res.* **2008**, *33*, 2416–2426.
- (11) Sobolewski, P.; Gramaglia, I.; Frangos, J.; Intaglietta, M.; van der Heyde, H. C. *Trends Parasitol.* **2005**, *21*, 415–422.
- (12) Matter, H.; Kotsonis, P. *Med. Res. Rev.* **2004**, *24*, 662–684.
- (13) Masic, L. P. *Curr. Med. Chem.* **2006**, *13*, 3627–3648.
- (14) Oess, S.; Icking, A.; Fulton, D.; Govers, R.; Muller-Esterl, W. *Biochem. J.* **2006**, *396*, 401–409.
- (15) Patman, J.; Bhardwaj, N.; Ramnauth, J.; Annedi, S. C.; Renton, P.; Maddaford, S. P.; Rakhit, S.; Andrews, J. S. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 2540–2544.
- (16) Hesslinger, C.; Strub, A.; Boer, R.; Ulrich, W. R.; Lehner, M. D.; Braun, C. *Biochem. Soc. Trans.* **2009**, *37*, 886–891.
- (17) Tsutsui, M.; Shimokawa, H.; Otsuji, Y.; Ueta, Y.; Sasaguri, Y.; Yanagihara, N. *Circ. J.* **2009**, *73*, 986–993.
- (18) Silverman, R. B. *Acc. Chem. Res.* **2009**, *42*, 439–451.
- (19) Maddaford, S.; Annedi, S. C.; Ramnauth, J.; Rakhit, S. *Annu. Rep. Med. Chem.* **2009**, *44*, 27–50.
- (20) Delker, S. L.; Ji, H. T.; Li, H. Y.; Jamal, J.; Fang, J. G.; Xue, F. T.; Silverman, R. B.; Poulos, T. L. *J. Am. Chem. Soc.* **2010**, *132*, 5437–5442.
- (21) Ji, H. T.; Delker, S. L.; Li, H. Y.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. *J. Med. Chem.* **2010**, *53*, 7804–7824.
- (22) Ji, H.; Stanton, B. Z.; Igarashi, J.; Li, H.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. *J. Am. Chem. Soc.* **2008**, *130*, 3900–3914.
- (23) Ji, H.; Li, H.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. *J. Med. Chem.* **2009**, *52*, 779–797.
- (24) Ji, H.; Tan, S.; Igarashi, J.; Li, H.; Derrick, M.; Martasek, P.; Roman, L. J.; Vásquez-Vivar, J.; Poulos, T. L.; Silverman, R. B. *Ann. Neurol.* **2009**, *65*, 209–217.
- (25) Flinspach, M. L.; Li, H. Y.; Jamal, J.; Yang, W. P.; Huang, H.; Hah, J. M.; Gomez-Vidal, J. A.; Litzinger, E. A.; Silverman, R. B.; Poulos, T. L. *Nat. Struct. Mol. Biol.* **2004**, *11*, 54–59.
- (26) Lawton, G. R.; Ranaivo, H. R.; Chico, L. K.; Ji, H. T.; Xue, F. T.; Martasek, P.; Roman, L. J.; Watterson, D. M.; Silverman, R. B. *Bioorg. Med. Chem.* **2009**, *17*, 2371–2380.
- (27) Xue, F.; Fang, J.; Lewis, W. W.; Martasek, P.; Roman, L. J.; Silverman, R. B. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 554–557.
- (28) Xue, F.; Li, H.; Delker, S. L.; Fang, J.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. *J. Am. Chem. Soc.* **2010**, *132*, 14229–14238.
- (29) Cui, Y. *J. Pharm. Sci.* **2011**, *100*, 2000–2019.
- (30) Genchev, G. Z.; Kallberg, M.; Gursoy, G.; Mittal, A.; Dubey, L.; Perisic, O.; Feng, G.; Langlois, R.; Lu, H. *Cell Biochem. Biophys.* **2009**, *55*, 141–152.
- (31) Sotomayor, M.; Schulten, K. *Science* **2007**, *316*, 1144–1148.
- (32) Mattos, C.; Rasmussen, B.; Ding, X.; Petsko, G. A.; Ringe, D. *Nat. Struct. Biol.* **1994**, *1*, 55–58.
- (33) Raman, C. S.; Li, H.; Martasek, P.; Southan, G.; Masters, B. S.; Poulos, T. L. *Biochemistry* **2001**, *40*, 13448–13455.
- (34) Ippolito, J. A.; Christianson, D. W. *Int. J. Biol. Macromol.* **1992**, *14*, 193–197.
- (35) Lu, Y. X.; Shi, T.; Wang, Y.; Yang, H. Y.; Yan, X. H.; Luo, X. M.; Jiang, H. L.; Zhu, W. L. *J. Med. Chem.* **2009**, *52*, 2854–2862.
- (36) Hunter, C. A.; Sanders, J. K. M. *J. Am. Chem. Soc.* **1990**, *112*, 5525–5534.
- (37) Cozzi, F.; Cinquini, M.; Annuziata, R.; Siegel, J. S. *J. Am. Chem. Soc.* **1993**, *115*, 5330–5331.
- (38) Fang, J. G.; Silverman, R. B. *Anal. Biochem.* **2009**, *390*, 74–78.
- (39) Linnet, K.; Ejsing, T. B. *Eur. Neuropsychopharmacol.* **2008**, *18*, 157–169.
- (40) Sanner, M. F. *J. Mol. Graph. Model.* **1999**, *17*, 57–61.
- (41) Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. *J. Comput. Chem.* **2009**, *30*, 2785–2791.
- (42) Gordon, J. C.; Myers, J. B.; Folta, T.; Shoja, V.; Heath, L. S.; Onufriev, A. *Nucleic Acids Res.* **2005**, *33*, W368–371.

- (43) Myers, J.; Grothaus, G.; Narayanan, S.; Onufriev, A. *Proteins: Struct., Funct., Bioinf.* **2006**, *63*, 928–938.
- (44) Hess, B.; Kutzner, C.; van der Spoel, D.; Lindahl, E. *J. Chem. Theory Comput.* **2008**, *4*, 435–447.
- (45) Van der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A. E.; Berendsen, H. J. C. *J. Comput. Chem.* **2005**, *26*, 1701–1718.
- (46) Oda, A.; Yamaotsu, N.; Hirono, S. *J. Comput. Chem.* **2005**, *26*, 818–826.
- (47) Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G. M.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J. M.; Kollman, P. *J. Comput. Chem.* **2003**, *24*, 1999–2012.
- (48) Mark, P.; Nilsson, L. *J. Phys. Chem. A* **2001**, *105*, 9954–9960.
- (49) Darden, T.; York, D.; Pedersen, L. *J. Chem. Phys.* **1993**, *98*, 10089–10092.
- (50) Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. *J. Chem. Phys.* **1995**, *103*, 8577–8593.
- (51) Xu, Y. C.; Shen, J. H.; Luo, X. M.; Silman, I.; Sussman, J. L.; Chen, K. X.; Jiang, H. L. *J. Am. Chem. Soc.* **2003**, *125*, 11340–11349.
- (52) Lemkul, J. A.; Bevan, D. R. *J. Phys. Chem. B* **2010**, *114*, 1652–1660.
- (53) Wallace, A. C.; Laskowski, R. A.; Thornton, J. M. *Protein Eng.* **1995**, *8*, 127–134.
- (54) Hevel, J. M.; White, K. A.; Marletta, M. A. *J. Biol. Chem.* **1991**, *266*, 22789–22791.
- (55) Roman, L. J.; Sheta, E. A.; Martasek, P.; Gross, S. S.; Liu, Q.; Masters, B. S. S. *Proc. Natl. Acad. Sci. U.S.A.* **1995**, *92*, 8428–8432.
- (56) Martasek, P.; Liu, Q.; Liu, J. W.; Roman, L. J.; Gross, S. S.; Sessa, W. C.; Masters, B. S. S. *Biochem. Biophys. Res. Commun.* **1996**, *219*, 359–365.
- (57) Hevel, J. M.; Marletta, M. A. *Oxygen Radicals Biol. Syst., C* **1994**, *233*, 250–258.
- (58) Li, H.; Shimizu, H.; Flinspach, M.; Jamal, J.; Yang, W.; Xian, M.; Cai, T.; Wen, E. Z.; Jia, Q.; Wang, P. G.; Poulos, T. L. *Biochemistry* **2002**, *41*, 13868–13875.
- (59) Flinspach, M. L.; Li, H.; Jamal, J.; Yang, W.; Huang, H.; Hah, J. M.; Gomez-Vidal, J. A.; Litzinger, E. A.; Silverman, R. B.; Poulos, T. L. *Nat. Struct. Mol. Biol.* **2004**, *11*, 54–59.
- (60) McPhillips, T. M.; McPhillips, S. E.; Chiu, H. J.; Cohen, A. E.; Deacon, A. M.; Ellis, P. J.; Garman, E.; Gonzalez, A.; Sauter, N. K.; Phizackerley, R. P.; Soltis, S. M.; Kuhn, P. *J. Synchrotron Radiat.* **2002**, *9*, 401–406.
- (61) Otwinowski, Z.; Minor, W. *Methods Enzymol.* **1997**, *276*, 307–326.
- (62) Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. *Acta Crystallogr.* **1997**, *D53*, 240–255.
- (63) Emsley, P.; Cowtan, K. *Acta Crystallogr.* **2004**, *D60*, 2126–2132.
- (64) Winn, M. D.; Isupov, M. N.; Murshudov, G. N. *Acta Crystallogr.* **2001**, *D57*, 122–133.